Regulatory easing to open the generic drug floodgates
The central drug regulator has exempted half of low-risk bioequivalence studies, making it easier for domestic generic drugs to be launched. This has reduced burden on pharmaceutical companies and freed up regulatory resources. Digitization of processes and development of a digital platform to streamline drug value chain have also been implemented.